Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

1. The European Commission has authorized expanded venetoclax (Venclyxto) combinations for previously untreated chronic lymphocytic leukemia.

2. The approval reinforces the continued movement toward fixed-duration, chemotherapy-free regimens in chronic lymphocytic leukemia care.

AbbVie has received European Commission authorization for expanded use of venetoclax (Venclyxto) in previously untreated chronic lymphocytic leukemia. The updated indication includes venetoclax with acalabrutinib, with or without obinutuzumab, as well as venetoclax with ibrutinib and the already established obinutuzumab regimen. This is a notable step because chronic lymphocytic leukemia treatment has changed rapidly over the past decade. For many patients, the field has moved away from traditional chemoimmunotherapy and toward oral targeted combinations that can be selected based on age, comorbidities, disease biology, and patient preference. The phase 3 AMPLIFY trial is a key part of the evidence base behind this shift. In that study, fixed-duration acalabrutinib and venetoclax-based regimens significantly improved progression-free survival compared with chemoimmunotherapy in fit, previously untreated patients. Three-year progression-free survival was 76.5% with acalabrutinib plus venetoclax and 83.1% with acalabrutinib, venetoclax, and obinutuzumab, compared with 66.5% with chemoimmunotherapy. Those data help explain why physicians are increasingly thinking beyond the question of whether targeted therapy belongs in first-line chronic lymphocytic leukemia. The more practical question is how to choose among fixed-duration combinations, continuous Bruton tyrosine kinase inhibition, and patient-specific safety considerations. Venetoclax remains particularly important because it offers a time-limited approach for some patients rather than indefinite therapy. That can matter a great deal for patients who are thinking about treatment burden, cost, monitoring, and long-term adverse effects. At the same time, these regimens still require careful attention to tumor lysis risk, infection risk, drug interactions, and patient fitness. For AbbVie, the expanded European label helps keep venetoclax central in a treatment landscape that has become increasingly competitive. The regulatory update is described in AbbVie’s announcement, with the AMPLIFY results published in The New England Journal of Medicine. For clinicians, the broader takeaway is that first-line chronic lymphocytic leukemia treatment is becoming more personalized, more targeted, and increasingly less dependent on conventional chemotherapy.